Boston Partners
GILD icon

Boston Partners’s Gilead Sciences GILD Stock Holding History

Boston Partners’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$762M Buy
6,017,958
+1,762,836
+41% +$232M 0.68% 40
2026
Q1 		$593M Buy
4,255,122
+34,621
+0.8% +$4.85M 0.62% 47
2025
Q4 		$518M Buy
+4,220,501
New +$513M 0.54% 57
2020
Q4 		– Sell
-4,456
Closed -$282K – 649
2020
Q3 		$282K Sell
4,456
-20,521
-82% -$1.42M ﹤0.01% 631
2020
Q2 		$1.92M Sell
24,977
-986,335
-98% -$75.6M ﹤0.01% 428
2020
Q1 		$75.6M Sell
1,011,312
-987,324
-49% -$68.2M 0.15% 169
2019
Q4 		$130M Sell
1,998,636
-211,567
-10% -$13.8M 0.17% 164
2019
Q3 		$140M Sell
2,210,203
-122,328
-5% -$8M 0.19% 152
2019
Q2 		$158M Sell
2,332,531
-3,572,977
-61% -$235M 0.21% 146
2019
Q1 		$384M Sell
5,905,508
-2,113,207
-26% -$140M 0.51% 57
2018
Q4 		$502M Sell
8,018,715
-360,174
-4% -$25.2M 0.72% 38
2018
Q3 		$647M Buy
8,378,889
+88,382
+1% +$6.67M 0.75% 37
2018
Q2 		$587M Buy
8,290,507
+245,805
+3% +$17.4M 0.7% 38
2018
Q1 		$606M Buy
8,044,702
+272,304
+4% +$21.6M 0.73% 34
2017
Q4 		$557M Sell
7,772,398
-2,652,391
-25% -$201M 0.66% 39
2017
Q3 		$845M Buy
10,424,789
+586,687
+6% +$44.9M 1.04% 16
2017
Q2 		$696M Sell
9,838,102
-379,895
-4% -$25.3M 0.89% 24
2017
Q1 		$694M Sell
10,217,997
-185,485
-2% -$13M 0.89% 23
2016
Q4 		$745M Buy
10,403,482
+547,800
+6% +$40.7M 0.98% 16
2016
Q3 		$780M Buy
9,855,682
+3,358,289
+52% +$273M 1.09% 10
2016
Q2 		$542M Sell
6,497,393
-92,107
-1% -$8.17M 0.78% 28
2016
Q1 		$605M Sell
6,589,500
-253,682
-4% -$22.9M 0.89% 25
2015
Q4 		$692M Buy
6,843,182
+93,588
+1% +$9.74M 0.99% 21
2015
Q3 		$663M Buy
6,749,594
+2,001,429
+42% +$222M 1.01% 19
2015
Q2 		$556M Buy
4,748,165
+501,586
+12% +$54.8M 0.8% 32
2015
Q1 		$417M Buy
4,246,579
+2,694,732
+174% +$274M 0.62% 44
2014
Q4 		$146M Buy
+1,551,847
New +$160M 0.22% 123

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Boston Partners's GILD Position: Q2 2026 in Review

Boston Partners increased its Gilead Sciences (GILD) stake by 41% in Q2 2026, buying an estimated $232M and bringing the position to 6,017,958 shares worth $762M. The position accounts for 0.68% of the portfolio, ranked #40.

Boston Partners first reported a position in GILD in Q4 2014 and has held it in 27 quarters since. The position peaked at $845M in Q3 2017. 2,283 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Boston Partners held 6,017,958 shares of Gilead Sciences worth $762M as of Q2 2026.
  • Boston Partners bought 1,762,836 Gilead Sciences shares in Q2 2026, an estimated $232M.
  • Gilead Sciences made up 0.68% of Boston Partners's portfolio in Q2 2026, its #40 holding.
  • Boston Partners first reported a position in Gilead Sciences in Q4 2014 and has held it in 27 quarters since.
  • Boston Partners's Gilead Sciences position peaked at $845M in Q3 2017.
  • 2,283 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Boston Partners's 13F filing for Q2 2026, filed 4 Aug 2026.